Substance / Medication

Azacitidine

Overview

Active Ingredient
azacitidine
RxNorm CUI
1251
Labeler: Apotex CorpUpdated: 2025-09-16T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis.
Hasegawa Ken, Wei Andrew H, Garcia-Manero Guillermo et al. · Clin Lymphoma Myeloma Leuk · 2023
PMID: 36428152Meta-Analysis
Azacitidine maintenance in AML post induction and posttransplant.
Bewersdorf Jan Philipp, Prebet Thomas, Gowda Lohith · Curr Opin Hematol · 2022
PMID: 35013047Meta-Analysis
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.
Almasri Jehad, Alkhateeb Hassan B, Firwana Belal et al. · Syst Rev · 2018
PMID: 30227896Meta-AnalysisFull text (PMC)
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji Rami, Swern Arlene S, Grinblatt David et al. · Oncologist · 2018
PMID: 29118268Meta-AnalysisFull text (PMC)
Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Xie Mixue, Jiang Qi, Xie Yanhui · Clin Lymphoma Myeloma Leuk · 2015
PMID: 25042977Meta-Analysis
Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
Kumar Ambuj, List Alan F, Hozo Iztok et al. · Haematologica · 2010
PMID: 19850902Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Azacitidine (substance)
SNOMED CT
412328000
UMLS CUI
C0004475
RxNorm CUI
1251
Labeler
Apotex Corp

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.